Another company which works in a similar space in India include Kasiak Research, which is a part of Bharat Serums and Vaccines (BSVL).

The Indian market is expected to open flat. Here is a list of top fifteen stocks that are likely to be in focus today.

The company's goal is to globalise Stempeucel for Buerger's Disease and the market size is approximately $ 1.5 billion worldwide.

Stempeutics has received process patent from the Japan for novel stem cell drug Stempeucel aimed at treatment of critical limb ischemia.

An orphan designation allows a company to benefit from incentives from the European Union to develop a medicine for a rare disease.

Stempeutics' stem cell-based drugs enable living tissues to repair or replace tissue or organ function lost due to age, disease, damage or ...

The ATMP classification, approved by the committee for Advanced Therapies (CAT) of the EMA will allow the Bengaluru- based Stempeutics to c...

At 09:40 a.m.; Cipla was trading 2.4 per cent higher at Rs 742.20. It hit a low of Rs 725 and a high of Rs 744.90 in trade today.

Backed by the Manipal Education and Medical Group and drug maker Cipla, Stempeutics makes stem cell-based drugs or regenerative medicine.

Demand for quality healthcare and easier access to capital have led to the launch of many startups working in such areas as new drug develo...